{"pmid":32305587,"pmcid":"PMC7162746","title":"Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals?","text":["Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals?","With ongoing global outbreak of coronavirus disease 2019 (COVID-19), management of exposure events is a concern. Long-term care hospitals (LTCHs) are especially vulnerable to cluster outbreaks, since it is difficult to find facilities and healthcare personnel for their separate isolation care in a large outbreak situation. Although several drugs have been proposed as treatment regimens, there are no data on the effectiveness and safety of post-exposure prophylaxis (PEP) for COVID-19. After a large COVID-19 exposure event in a LTCH in Korea, PEP using hydroxychloroquine (HCQ) was conducted to 211 persons including 189 patients and 22 careworkers, whose baseline polymerase chain reaction (PCR) tests for COVID-19 were negative. PEP was completed in 184 (97.4%) patients and 21 (95.5%) careworkers without serious adverse events. At the end of 14 days of quarantine, follow-up PCR tests were all negative. Based on our experience, further clinical studies would be conducted for COVID-19 PEP.","Int J Antimicrob Agents","Lee, Sun Hee","Son, Hyunjin","Peck, Kyong Ran","32305587"],"abstract":["With ongoing global outbreak of coronavirus disease 2019 (COVID-19), management of exposure events is a concern. Long-term care hospitals (LTCHs) are especially vulnerable to cluster outbreaks, since it is difficult to find facilities and healthcare personnel for their separate isolation care in a large outbreak situation. Although several drugs have been proposed as treatment regimens, there are no data on the effectiveness and safety of post-exposure prophylaxis (PEP) for COVID-19. After a large COVID-19 exposure event in a LTCH in Korea, PEP using hydroxychloroquine (HCQ) was conducted to 211 persons including 189 patients and 22 careworkers, whose baseline polymerase chain reaction (PCR) tests for COVID-19 were negative. PEP was completed in 184 (97.4%) patients and 21 (95.5%) careworkers without serious adverse events. At the end of 14 days of quarantine, follow-up PCR tests were all negative. Based on our experience, further clinical studies would be conducted for COVID-19 PEP."],"journal":"Int J Antimicrob Agents","authors":["Lee, Sun Hee","Son, Hyunjin","Peck, Kyong Ran"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305587","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ijantimicag.2020.105988","keywords":["covid-19","hydroxychloroquine","long-term care hospital","post-exposure prophylaxis","sars-cov-2"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["South Korea"],"countries":["Korea, Republic of"],"countries_codes":["KOR|Korea, Republic of"],"e_drugs":["Hydroxychloroquine"],"_version_":1664641855713705984,"score":8.518259,"similar":[{"pmid":32260436,"title":"Wearable Cardiorespiratory Monitoring Employing a Multimodal Digital Patch Stethoscope: Estimation of ECG, PEP, LVETand Respiration Using a 55 mm Single-Lead ECG and Phonocardiogram.","text":["Wearable Cardiorespiratory Monitoring Employing a Multimodal Digital Patch Stethoscope: Estimation of ECG, PEP, LVETand Respiration Using a 55 mm Single-Lead ECG and Phonocardiogram.","Cardiovascular diseases are the main cause of death worldwide, with sleep disordered breathing being a further aggravating factor. Respiratory illnesses are the third leading cause of death amongst the noncommunicable diseases. The current COVID-19 pandemic, however, also highlights the impact of communicable respiratory syndromes. In the clinical routine, prolonged postanesthetic respiratory instability worsens the patient outcome. Even though early and continuous, long-term cardiorespiratory monitoring has been proposed or even proven to be beneficial in several situations, implementations thereof are sparse. We employed our recently presented, multimodal patch stethoscope to estimate Einthoven electrocardiogram (ECG) Lead I and II from a single 55 mm ECG lead. Using the stethoscope and ECG subsystems, the pre-ejection period (PEP) and left ventricular ejection time (LVET) were estimated. ECG-derived respiration techniques were used in conjunction with a novel, phonocardiogram-derived respiration approach to extract respiratory parameters. Medical-grade references were the SOMNOmedics SOMNO HD(TM) and Osypka ICON-Core(TM). In a study including 10 healthy subjects, we analyzed the performances in the supine, lateral, and prone position. Einthoven I and II estimations yielded correlations exceeding 0.97. LVET and PEP estimation errors were 10% and 21%, respectively. Respiratory rates were estimated with mean absolute errors below 1.2 bpm, and the respiratory signal yielded a correlation of 0.66. We conclude that the estimation of ECG, PEP, LVET, and respiratory parameters is feasible using a wearable, multimodal acquisition device and encourage further research in multimodal signal fusion for respiratory signal estimation.","Sensors (Basel)","Klum, Michael","Urban, Mike","Tigges, Timo","Pielmus, Alexandru-Gabriel","Feldheiser, Aarne","Schmitt, Theresa","Orglmeister, Reinhold","32260436"],"abstract":["Cardiovascular diseases are the main cause of death worldwide, with sleep disordered breathing being a further aggravating factor. Respiratory illnesses are the third leading cause of death amongst the noncommunicable diseases. The current COVID-19 pandemic, however, also highlights the impact of communicable respiratory syndromes. In the clinical routine, prolonged postanesthetic respiratory instability worsens the patient outcome. Even though early and continuous, long-term cardiorespiratory monitoring has been proposed or even proven to be beneficial in several situations, implementations thereof are sparse. We employed our recently presented, multimodal patch stethoscope to estimate Einthoven electrocardiogram (ECG) Lead I and II from a single 55 mm ECG lead. Using the stethoscope and ECG subsystems, the pre-ejection period (PEP) and left ventricular ejection time (LVET) were estimated. ECG-derived respiration techniques were used in conjunction with a novel, phonocardiogram-derived respiration approach to extract respiratory parameters. Medical-grade references were the SOMNOmedics SOMNO HD(TM) and Osypka ICON-Core(TM). In a study including 10 healthy subjects, we analyzed the performances in the supine, lateral, and prone position. Einthoven I and II estimations yielded correlations exceeding 0.97. LVET and PEP estimation errors were 10% and 21%, respectively. Respiratory rates were estimated with mean absolute errors below 1.2 bpm, and the respiratory signal yielded a correlation of 0.66. We conclude that the estimation of ECG, PEP, LVET, and respiratory parameters is feasible using a wearable, multimodal acquisition device and encourage further research in multimodal signal fusion for respiratory signal estimation."],"journal":"Sensors (Basel)","authors":["Klum, Michael","Urban, Mike","Tigges, Timo","Pielmus, Alexandru-Gabriel","Feldheiser, Aarne","Schmitt, Theresa","Orglmeister, Reinhold"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32260436","week":"202015|Apr 06 - Apr 12","doi":"10.3390/s20072033","keywords":["ecg","ecg-derived respiration","lvet","pep","digital stethoscope","neural network","patch","phonocardiogram-derived respiration","respiration rate","wearable cardiorespiratory monitoring"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664637636115955713,"score":335.81247},{"pmid":32292817,"pmcid":"PMC7128742","title":"Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19.","text":["Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19.","Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people, meaning people with close contact with positive tested patients, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at does matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6mg/kg/day 1 (loading dose) followed by 5mg/kg/day, with a maximum limit of 600mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people.","One Health","Picot, Stephane","Marty, Aileen","Bienvenu, Anne-Lise","Blumberg, Lucille H","Dupouy-Camet, Jean","Carnevale, Pierre","Kano, Shigeyuki","Jones, Malcolm K","Daniel-Ribeiro, Claudio Tadeu","Mas-Coma, Santiago","32292817"],"abstract":["Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people, meaning people with close contact with positive tested patients, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at does matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6mg/kg/day 1 (loading dose) followed by 5mg/kg/day, with a maximum limit of 600mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people."],"journal":"One Health","authors":["Picot, Stephane","Marty, Aileen","Bienvenu, Anne-Lise","Blumberg, Lucille H","Dupouy-Camet, Jean","Carnevale, Pierre","Kano, Shigeyuki","Jones, Malcolm K","Daniel-Ribeiro, Claudio Tadeu","Mas-Coma, Santiago"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292817","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.onehlt.2020.100131","keywords":["covid19","chloroquine","hydroxychloroquine","immunomodulation","sars-cov2","systemic lupus erythematosus"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Hydroxychloroquine"],"_version_":1664636192768917505,"score":282.25333},{"pmid":32327397,"title":"Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.","text":["Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.","BACKGROUND: Combinations of hydroxychloroquine (HCQ) and azithromycin have been promoted as treatments for COVID-19 based on small, uncontrolled clinical trials that have not assessed potential risks. Risks of treatment include QT segment prolongation, Torsades de Pointes (TdP), and death. This comparative pharmacovigilance analysis evaluated the risk of these events. METHODS: Data from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) (>13 million total reports) were used. Queries extracted reports based on exposures of HCQ/chloroquine (CQ) alone, azithromycin alone, HCQ/CQ + azithromycin, amoxicillin alone, HCQ/CQ + amoxicillin alone. Amoxicillin served as a control. Events of interest included death and TdP/QT prolongation as well as accidents/injuries and depression as control events. Proportional Reporting Ratios (PRR) and 95% confidence intervals (CI) were calculated where a lower limit of the of 95% CI (Lower95CI) value of >/=2.0 is interpreted as a potential safety signal. RESULTS: Lower95CIs for HCQ/CQ alone showed no potential safety signals for TdP/QT prolongation, death, or any of the control events included. The PRRs and 95% CIs for TdP/QT prolongation was 1.43 (1.29-2.59) with HCQ/CQ use alone and 4.10 (3.80-4.42) for azithromycin alone. For the combined HCQ/CQ + azithromycin group, the PRR and 95% CI was 3.77 (1.80-7.87). For the control of amoxicillin, there were no safety signals when used alone or in combination with HCQ/CQ. CONCLUSIONS: HCQ/CQ use was not associated with a safety signal in this analysis of FAERS data. However, azithromycin used alone was associated with TdP/QT prolongation events and should be used with caution.","Res Social Adm Pharm","Sarayani, Amir","Cicali, Brian","Henriksen, Carl H","Brown, Joshua D","32327397"],"abstract":["BACKGROUND: Combinations of hydroxychloroquine (HCQ) and azithromycin have been promoted as treatments for COVID-19 based on small, uncontrolled clinical trials that have not assessed potential risks. Risks of treatment include QT segment prolongation, Torsades de Pointes (TdP), and death. This comparative pharmacovigilance analysis evaluated the risk of these events. METHODS: Data from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) (>13 million total reports) were used. Queries extracted reports based on exposures of HCQ/chloroquine (CQ) alone, azithromycin alone, HCQ/CQ + azithromycin, amoxicillin alone, HCQ/CQ + amoxicillin alone. Amoxicillin served as a control. Events of interest included death and TdP/QT prolongation as well as accidents/injuries and depression as control events. Proportional Reporting Ratios (PRR) and 95% confidence intervals (CI) were calculated where a lower limit of the of 95% CI (Lower95CI) value of >/=2.0 is interpreted as a potential safety signal. RESULTS: Lower95CIs for HCQ/CQ alone showed no potential safety signals for TdP/QT prolongation, death, or any of the control events included. The PRRs and 95% CIs for TdP/QT prolongation was 1.43 (1.29-2.59) with HCQ/CQ use alone and 4.10 (3.80-4.42) for azithromycin alone. For the combined HCQ/CQ + azithromycin group, the PRR and 95% CI was 3.77 (1.80-7.87). For the control of amoxicillin, there were no safety signals when used alone or in combination with HCQ/CQ. CONCLUSIONS: HCQ/CQ use was not associated with a safety signal in this analysis of FAERS data. However, azithromycin used alone was associated with TdP/QT prolongation events and should be used with caution."],"journal":"Res Social Adm Pharm","authors":["Sarayani, Amir","Cicali, Brian","Henriksen, Carl H","Brown, Joshua D"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327397","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.sapharm.2020.04.016","keywords":["azithromycin","covid-19","hydroxychloroquine","qt prolongation","sars-cov-2","torsades de pointes"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["amoxicillin"],"e_drugs":["Hydroxychloroquine","Chloroquine","Amoxicillin","Azithromycin"],"_version_":1664996915016630272,"score":253.36969},{"pmid":32298249,"title":"Transmission of COVID-19 to Health Care Personnel During Exposures to a Hospitalized Patient - Solano County, California, February 2020.","text":["Transmission of COVID-19 to Health Care Personnel During Exposures to a Hospitalized Patient - Solano County, California, February 2020.","On February 26, 2020, the first U.S. case of community-acquired coronavirus disease 2019 (COVID-19) was confirmed in a patient hospitalized in Solano County, California (1). The patient was initially evaluated at hospital A on February 15; at that time, COVID-19 was not suspected, as the patient denied travel or contact with symptomatic persons. During a 4-day hospitalization, the patient was managed with standard precautions and underwent multiple aerosol-generating procedures (AGPs), including nebulizer treatments, bilevel positive airway pressure (BiPAP) ventilation, endotracheal intubation, and bronchoscopy. Several days after the patient's transfer to hospital B, a real-time reverse transcription-polymerase chain reaction (real-time RT-PCR) test for SARS-CoV-2 returned positive. Among 121 hospital A health care personnel (HCP) who were exposed to the patient, 43 (35.5%) developed symptoms during the 14 days after exposure and were tested for SARS-CoV-2; three had positive test results and were among the first known cases of probable occupational transmission of SARS-CoV-2 to HCP in the United States. Little is known about specific risk factors for SARS-CoV-2 transmission in health care settings. To better characterize and compare exposures among HCP who did and did not develop COVID-19, standardized interviews were conducted with 37 hospital A HCP who were tested for SARS-CoV-2, including the three who had positive test results. Performing physical examinations and exposure to the patient during nebulizer treatments were more common among HCP with laboratory-confirmed COVID-19 than among those without COVID-19; HCP with COVID-19 also had exposures of longer duration to the patient. Because transmission-based precautions were not in use, no HCP wore personal protective equipment (PPE) recommended for COVID-19 patient care during contact with the index patient. Health care facilities should emphasize early recognition and isolation of patients with possible COVID-19 and use of recommended PPE to minimize unprotected, high-risk HCP exposures and protect the health care workforce.","MMWR Morb Mortal Wkly Rep","Heinzerling, Amy","Stuckey, Matthew J","Scheuer, Tara","Xu, Kerui","Perkins, Kiran M","Resseger, Heather","Magill, Shelley","Verani, Jennifer R","Jain, Seema","Acosta, Meileen","Epson, Erin","32298249"],"abstract":["On February 26, 2020, the first U.S. case of community-acquired coronavirus disease 2019 (COVID-19) was confirmed in a patient hospitalized in Solano County, California (1). The patient was initially evaluated at hospital A on February 15; at that time, COVID-19 was not suspected, as the patient denied travel or contact with symptomatic persons. During a 4-day hospitalization, the patient was managed with standard precautions and underwent multiple aerosol-generating procedures (AGPs), including nebulizer treatments, bilevel positive airway pressure (BiPAP) ventilation, endotracheal intubation, and bronchoscopy. Several days after the patient's transfer to hospital B, a real-time reverse transcription-polymerase chain reaction (real-time RT-PCR) test for SARS-CoV-2 returned positive. Among 121 hospital A health care personnel (HCP) who were exposed to the patient, 43 (35.5%) developed symptoms during the 14 days after exposure and were tested for SARS-CoV-2; three had positive test results and were among the first known cases of probable occupational transmission of SARS-CoV-2 to HCP in the United States. Little is known about specific risk factors for SARS-CoV-2 transmission in health care settings. To better characterize and compare exposures among HCP who did and did not develop COVID-19, standardized interviews were conducted with 37 hospital A HCP who were tested for SARS-CoV-2, including the three who had positive test results. Performing physical examinations and exposure to the patient during nebulizer treatments were more common among HCP with laboratory-confirmed COVID-19 than among those without COVID-19; HCP with COVID-19 also had exposures of longer duration to the patient. Because transmission-based precautions were not in use, no HCP wore personal protective equipment (PPE) recommended for COVID-19 patient care during contact with the index patient. Health care facilities should emphasize early recognition and isolation of patients with possible COVID-19 and use of recommended PPE to minimize unprotected, high-risk HCP exposures and protect the health care workforce."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Heinzerling, Amy","Stuckey, Matthew J","Scheuer, Tara","Xu, Kerui","Perkins, Kiran M","Resseger, Heather","Magill, Shelley","Verani, Jennifer R","Jain, Seema","Acosta, Meileen","Epson, Erin"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298249","week":"202016|Apr 13 - Apr 19","doi":"10.15585/mmwr.mm6915e5","source":"PubMed","topics":["Transmission","Prevention"],"weight":1,"locations":["USA","Solano County","California","nebulizer","United States","nebulizer","California"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664641388245942272,"score":246.0536},{"pmid":32247211,"pmcid":"PMC7102587","title":"Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.","text":["Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.","BACKGROUND AND AIMS: No drugs are currently approved for Coronavirus Disease-2019 (COVID-19), although some have been tried. In view of recent studies and discussion on chloroquine and hydroxychloroquine (HCQ), we aimed to review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines. AIMS AND METHODS: We systematically searched the PubMed database up till March 21, 2020 and retrieved all the articles published on chloroquine and HCQ and COVID-19. RESULTS: Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19. CONCLUSION: Considering minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across India, we propose that both these drugs are worthy of fast track clinical trial for treatment, and may be carefully considered for clinical use as experimental drugs. Since HCQ has been approved for treatment of diabetes in India, it should be further researched in diabetes and COVID-19, a subgroup where significant mortality has been shown.","Diabetes Metab Syndr","Singh, Awadhesh Kumar","Singh, Akriti","Shaikh, Altamash","Singh, Ritu","Misra, Anoop","32247211"],"abstract":["BACKGROUND AND AIMS: No drugs are currently approved for Coronavirus Disease-2019 (COVID-19), although some have been tried. In view of recent studies and discussion on chloroquine and hydroxychloroquine (HCQ), we aimed to review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines. AIMS AND METHODS: We systematically searched the PubMed database up till March 21, 2020 and retrieved all the articles published on chloroquine and HCQ and COVID-19. RESULTS: Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19. CONCLUSION: Considering minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across India, we propose that both these drugs are worthy of fast track clinical trial for treatment, and may be carefully considered for clinical use as experimental drugs. Since HCQ has been approved for treatment of diabetes in India, it should be further researched in diabetes and COVID-19, a subgroup where significant mortality has been shown."],"journal":"Diabetes Metab Syndr","authors":["Singh, Awadhesh Kumar","Singh, Akriti","Shaikh, Altamash","Singh, Ritu","Misra, Anoop"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247211","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.dsx.2020.03.011","keywords":["covid-19","chloroquine","diabetes","hydroxychloroquine"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["India","India","India"],"countries":["India"],"countries_codes":["IND|India"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"_version_":1664638040178425858,"score":222.69772}]}